Relapsing-remitting multiple sclerosis and Hepatitis fulminant

Summary:

Hepatitis fulminant is found among people with Relapsing-remitting multiple sclerosis, especially for people who are female, 40-49 old.

The study analyzes which people have Hepatitis fulminant with Relapsing-remitting multiple sclerosis. It is created by eHealthMe based on reports of 13 people who have Relapsing-remitting multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

What is Hepatitis fulminant?

Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function) is found to be associated with 450 drugs and 677 conditions by eHealthMe. Check the latest studies of Hepatitis fulminant.



On Jul, 26, 2026

13 people who have Relapsing-Remitting Multiple Sclerosis and Hepatitis Fulminant are studied.

Would you have Hepatitis fulminant when you have Relapsing-remitting multiple sclerosis?

Gender of people who have Relapsing-Remitting Multiple Sclerosis and experienced Hepatitis Fulminant *:

  • female: 83.33 %
  • male: 16.67 %

Age of people who have Relapsing-Remitting Multiple Sclerosis and experienced Hepatitis Fulminant *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 9.09 %
  • 30-39: 18.18 %
  • 40-49: 63.64 %
  • 50-59: 9.09 %
  • 60+: 0.0 %

Common co-existing conditions for these people *:

  1. Neuralgia (pain in one or more nerves): 3 people, 23.08%
  2. Influenza Like Illness: 3 people, 23.08%
  3. Vaginal Bleeding Between Periods: 2 people, 15.38%
  4. Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 15.38%
  5. Nausea And Vomiting: 2 people, 15.38%
  6. High Blood Pressure: 2 people, 15.38%
  7. Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 2 people, 15.38%
  8. Headache (pain in head): 2 people, 15.38%
  9. Fever: 2 people, 15.38%
  10. Dysaesthesia (abnormal sensation): 2 people, 15.38%

Common drugs taken by these people *:

  1. Lyrica: 5 people, 38.46%
  2. Tysabri: 4 people, 30.77%
  3. Zantac: 2 people, 15.38%
  4. Konakion: 2 people, 15.38%
  5. Lantus: 2 people, 15.38%
  6. Humalog: 2 people, 15.38%
  7. Pantoprazole: 2 people, 15.38%
  8. Paracetamol: 2 people, 15.38%
  9. Prometrium: 2 people, 15.38%
  10. Bactrim: 2 people, 15.38%

Common symptoms for these people *:

  1. Hepatic Failure (liver failure): 3 people, 23.08%
  2. Hepatic Necrosis (large portions of liver die off due to severe liver disease): 2 people, 15.38%
  3. Ascites (accumulation of fluid in the abdominal cavity): 2 people, 15.38%
  4. Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 15.38%
  5. Autoimmune Hepatitis: 2 people, 15.38%
  6. Hepatitis Viral: 2 people, 15.38%
  7. Epstein-Barr Virus Infection: 1 person, 7.69%
  8. Enterococcus Test Positive: 1 person, 7.69%
  9. Gait Disturbance: 1 person, 7.69%
  10. Cytomegalovirus Infection: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Hepatitis fulminant?

- Check whether Hepatitis fulminant is associated with a drug or a condition


Related publications that referenced our studies

Related studies:

Treatments, associated drugs and conditions:

All the drugs that are associated with Hepatitis fulminant:

All the conditions that are associated with Hepatitis fulminant:


How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Hepatitis fulminant and Relapsing-remitting multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: